FAIRFIELD, N.J., Feb. 10 /PRNewswire-FirstCall/ -- BRADLEY
PHARMACEUTICALS, INC. (NYSE: BDY) today announced that Leonard S. Jacob, M.D.,
Ph.D., and William J. Murphy, CPA, have been elected to Bradley's Board of
Directors.
Dr. Jacob, who will serve as Chairman of the Board's Nominating and
Corporate Governance Committee, brings to Bradley over 28 years of medical and
pharmaceutical industry experience. During 1997, Dr. Jacob founded InKine
Pharmaceutical Company, Inc., a specialty pharmaceutical company that
developed and commercialized gastrointestinal products including Visicol, a
tablet alternative preparation for colonoscopy, and IBStat, a treatment for
Irritable Bowel Syndrome. Dr. Jacob served as Chairman and CEO of InKine from
1997 until the company was acquired by Salix Pharmaceuticals in September
2005. In 1989, Dr. Jacob co-founded Magainin Pharmaceuticals and served as
the company's Chief Operating Officer until 1996. From 1980 to 1989, Dr. Jacob
served as Worldwide Vice President of SmithKline Beecham Corp. (now Glaxo-
SmithKline). Dr. Jacob earned a Ph.D. in pharmacology from Temple University
in 1975 and an M.D. from the Medical College of Pennsylvania (now Drexel
University College of Medicine). Dr. Jacob currently serves on the Board of
Directors for the Colon Cancer Alliance and the Board of Overseers for Temple
University School of Medicine. In addition Dr. Jacob is the founding Director
of the Jacob Internet Fund, a public mutual fund, as well as MacroMed, Inc.
and Glyconix Corp., both private drug delivery companies.
Mr. Murphy, who will serve as a member of the Board's Audit Committee,
brings to Bradley over 28 years of experience in public accounting, with
extensive expertise in the challenges facing middle market, publicly held
companies. From 1997 to 2005, Mr. Murphy was with Computer Horizons Corp., an
information technology professional services company, serving first as
Executive Vice President and Chief Financial Officer. Beginning in March 2003
until October 2005, Mr. Murphy served as President and CEO. From 1980 to 1997,
Mr. Murphy was with the accounting firm of Grant Thornton LLP, which he joined
as Senior Audit Manager. From 1984 to 1990, Mr. Murphy served as audit
partner, and advanced to the role of partner in charge of its New Jersey
practice in 1990. Previously, Mr. Murphy served as Senior Audit Manager for
the accounting firm of Price Waterhouse, which he joined upon leaving the
United States Army, where he achieved the rank of Captain. Mr. Murphy
graduated from Seton Hall University and is a member of the New Jersey State
Society of CPAs, the American Institute of Certified Public Accountants and
the Financial Executives Institutes. Mr. Murphy has served as a Director of
the Commerce and Industry Association of New Jersey and is active in the CEO
Roundtable group of the Association for Corporate Growth.
Bradley President and CEO, Daniel Glassman, stated, "Bradley
Pharmaceuticals is excited to welcome Mr. Murphy and Dr. Jacob, both highly
experienced and successful professionals in their specialties, to the Board of
Directors. The Management Team, together with the Board of Directors, look
forward to their contributions to corporate strategic planning. Mr. Murphy's
financial expertise coupled with Dr. Jacob's extensive background in
pharmaceuticals will bring additional insight to Bradley's Board."
Please visit Bradley Pharmaceuticals web site at:
http://www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the
symbol BDY.
Bradley Pharmaceuticals, Inc. (NYSE: BDY) was founded in 1985 as a
specialty pharmaceutical company and markets to niche physician specialties in
the U.S. and 38 international markets. Bradley's success is based on the
strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands,
Enhances these brands with line extensions and improved formulations and Grows
the products through promotion, advertising and selling activities to optimize
life cycle management. Bradley Pharmaceuticals is comprised of Doak
Dermatologics, specializing in topical therapies for dermatology and podiatry;
Kenwood Therapeutics, providing gastroenterology, respiratory and other
internal medicine brands; and A. Aarons, which will market authorized generic
versions of Doak and Kenwood therapies.
Important announcement:
Doak Dermatologics continues its dedicated support of the American Academy
of Dermatology that dates to the organization's inception. Doak will be an
Emerald sponsor of the 64th Annual Meeting of the AAD, to be held in San
Francisco, CA, March 3-7, 2006.
Daniel Glassman will present the MediGene AG POLYPHENON(R) E Ointment
agreement at an Investor Conference while at the AAD meeting in San Francisco,
CA, March 3, 2006.
Daniel Glassman will present at the Raymond James & Associates 27th Annual
Institutional Investors Conference, Hyatt Regency Grand Cypress in Orlando,
FL, March 5-8th, 2006.
MediGene AG POLYPHENON(R) E Ointment agreement to be presented at an
Investor Conference, in Frankfort, Germany. March 22, 2006
Daniel Glassman will present at the CIBC World Markets Annual Specialty
Pharmaceutical & Biotechnology Conference, to be held at the Millenium
Broadway Hotel in New York City, April 4-5, 2006.
Daniel Glassman will present at the Banc of America Securities LLC, Health
Care Conference 2006, to be held at The Four Seasons Hotel in Las Vegas, NV,
May 16-18th, 2006.
Daniel Glassman will present a case study on Optimizing Lifecycle
Management for a Product with Limited Patent Protection at the MedAd News'
Specialty Pharmaceuticals Summit, June 6-8, 2006 at 8:45 AM at the Park Hyatt,
Philadelphia, PA.
SOURCE Bradley Pharmaceuticals, Inc.
 back to top
Related links:
http://www.bradpharm.com
CONTACT:
Anthony Griffo, Investor Relations of Bradley
Pharmaceuticals, Inc., +1-973-882-1505, ext. 313
|
